AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data.
Pharma giant AbbVie has been taken to task by the FDA for running an ad for one of its migraine drugs, featuring tennis star Serena Williams, which the agency says overstates its efficacy.<
Shares in Neurocrine Bioscience took a tumble after the company reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors.
AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuste